59 related articles for article (PubMed ID: 17343825)
1. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.
Hashimoto K; Morishige K; Sawada K; Ogata S; Tahara M; Shimizu S; Sakata M; Tasaka K; Kimura T
Biochem Biophys Res Commun; 2007 Apr; 356(1):72-7. PubMed ID: 17343825
[TBL] [Abstract][Full Text] [Related]
2. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro.
Hashimoto K; Morishige K; Sawada K; Tahara M; Shimizu S; Sakata M; Tasaka K; Murata Y
Cancer; 2005 Apr; 103(7):1529-36. PubMed ID: 15739201
[TBL] [Abstract][Full Text] [Related]
3. Geranylgeranylacetone blocks doxorubicin-induced cardiac toxicity and reduces cancer cell growth and invasion through RHO pathway inhibition.
Sysa-Shah P; Xu Y; Guo X; Pin S; Bedja D; Bartock R; Tsao A; Hsieh A; Wolin MS; Moens A; Raman V; Orita H; Gabrielson KL
Mol Cancer Ther; 2014 Jul; 13(7):1717-28. PubMed ID: 24737026
[TBL] [Abstract][Full Text] [Related]
4. Isoprenoid geranylgeranylacetone inhibits human colon cancer cells through induction of apoptosis and cell cycle arrest.
Yoshikawa N; Tsuno NH; Okaji Y; Kawai K; Shuno Y; Nagawa H; Oshima N; Takahashi K
Anticancer Drugs; 2010 Oct; 21(9):850-60. PubMed ID: 20724917
[TBL] [Abstract][Full Text] [Related]
5. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
7. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
Sawada K; Morishige K; Tahara M; Kawagishi R; Ikebuchi Y; Tasaka K; Murata Y
Cancer Res; 2002 Nov; 62(21):6015-20. PubMed ID: 12414621
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
9. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
12. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
Montero JC; García-Alonso S; Ocaña A; Pandiella A
Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
[TBL] [Abstract][Full Text] [Related]
13. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Lin YJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
[TBL] [Abstract][Full Text] [Related]
14. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid signals through mitogen-activated protein kinase-extracellular signal regulated kinase in ovarian theca cells expressing the LPA1/edg2-receptor: involvement of a nonclassical pathway?
Budnik LT; Brunswig-Spickenheier B; Mukhopadhyay AK
Mol Endocrinol; 2003 Aug; 17(8):1593-606. PubMed ID: 12730329
[TBL] [Abstract][Full Text] [Related]
17. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
18. Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation.
Wei H; Xu L; Yu M; Zhang L; Wang H; Wei X; Ruan Y
Chembiochem; 2012 Feb; 13(3):465-75. PubMed ID: 22253097
[TBL] [Abstract][Full Text] [Related]
19. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]